Prospective phase II trial of fulvestrant in the treatment of recurrent ovarian carcinoma

被引：0
|
作者：
Thomas, S. G. [1 ]
Judson, P. L. [1 ]
Carson, L. F. [1 ]
Downs, L. S. [1 ]
Ghebre, R. [1 ]
Geller, M. A. [1 ]
Jonson, A. L. [1 ]
Argenta, P. A. [1 ]
机构：
[1] Univ Minnesota, Minneapolis, MN USA
来源：
GYNECOLOGIC ONCOLOGY | 2009年 / 112卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
58
引用
收藏
页码：S32 / S32
页数：1
相关论文
共 50 条
  • [21] Delta tocotrienol in recurrent ovarian cancer. A phase II trial
    Thomsen, Caroline Brenner
    Andersen, Rikke Fredslund
    Steffensen, Karina Dahl
    Adimi, Parvin
    Jakobsen, Anders
    PHARMACOLOGICAL RESEARCH, 2019, 141 : 392 - 396
  • [22] Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer
    Burger, RA
    DiSaia, PJ
    Roberts, JA
    O'Rourke, M
    Gershenson, DM
    Homesley, HD
    Lichtman, SM
    Barnes, W
    Moore, DH
    Monk, BJ
    GYNECOLOGIC ONCOLOGY, 1999, 72 (02) : 148 - 153
  • [23] Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer
    Ghosh, Jaya
    Kumar, Lalit
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2008, 29 (03) : 7 - U37
  • [24] A phase II trial of combination nivolumab and bevacizumab in recurrent ovarian cancer
    Liu, J. F.
    Herold, C.
    Luo, W.
    Penson, R.
    Horowitz, N.
    Konstantinopoulos, P.
    Castro, C.
    Curtis, J.
    Matulonis, U. A.
    Cannistra, S.
    Dizon, D. S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [25] A phase II study of liposomal doxorubicin in recurrent epithelial ovarian carcinoma
    Arcuri, C
    Sorio, R
    Tognon, G
    Gambino, A
    Scalone, S
    Lucenti, A
    Caffo, O
    Valduga, F
    Arisi, E
    Galligioni, E
    TUMORI, 2004, 90 (06) : 556 - 561
  • [26] A PHASE-II STUDY OF TAMOXIFEN IN RECURRENT OVARIAN-CARCINOMA
    HARVEY, VJ
    OSBORNE, RJ
    SLEVIN, M
    MEDICAL AND PEDIATRIC ONCOLOGY, 1987, 15 (03): : 147 - 147
  • [27] Phase II trial of fenretinide (4-HPR) in recurrent ovarian and primary peritoneal carcinoma: A California Cancer Consortium trial
    Garcia, AA
    Morgan, R
    McNamara, M
    Scudder, S
    Tsao-Wei, D
    Groshen, S
    Frgala, T
    Kim, Y
    Reynolds, CP
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 463S - 463S
  • [28] Phase II clinical trial of cabozantinib for the treatment of recurrent hepatocellular carcinoma after liver transplantation
    Azhie, Amirhossein
    Grant, Robert C.
    Herman, Michael
    Wang, Lisa
    Knox, Jennifer J.
    Bhat, Mamatha
    FUTURE ONCOLOGY, 2022, 18 (18) : 2173 - 2191
  • [29] Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial
    Lorusso, D.
    Scambia, G.
    Pignata, S.
    Sorio, R.
    Amadio, G.
    Lepori, S.
    Mosconi, A.
    Pisano, C.
    Mangili, G.
    Maltese, G.
    Sabbatini, R.
    Artioli, G.
    Gamucci, T.
    Di Napoli, M.
    Capoluongo, E.
    Ludovini, V.
    Raspagliesi, F.
    Ferrandina, G.
    ANNALS OF ONCOLOGY, 2016, 27 (03) : 487 - 493
  • [30] Phase II trial of imatinib mesylate (I) in combination with docetaxel (D) in the treatment of patients (pts) with recurrent or persistent epithelial ovarian carcinoma (EOC)
    Usha, L.
    Larson, M. L.
    Kazmi, N.
    O'Brien, T.
    Winkelman, L. A.
    Rotmensch, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345